Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003376 · ClinicalTrials.gov registry record · Phase 3
Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
NCT00003376 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 330 participants.
The verdict
NCT00003376, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if four-drug combination chemotherapy is more effective than two-drug combination chemotherapy in treating advanced cancer of the urothelium. PURPOSE: Randomized phase III trial to compare the effectiveness of four-drug combination chemotherapy with that of two-drug combination chemotherapy in treating patients who have advanced cancer of the urothelium.
Interventions
- DRUG cisplatin
- DRUG carboplatin
- DRUG paclitaxel
- DRUG methotrexate
- DRUG doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 1998-12-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003376
The ClinicalTrials.gov registry entry for NCT00003376 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00003376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003376 about?
NCT00003376 is a clinical study titled "Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if four-drug combination chemotherapy is more effective than two-drug combination chemotherapy in treati...
What is the current status of trial NCT00003376?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 1998-12-03.
What interventions are being tested in trial NCT00003376?
The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), paclitaxel (DRUG), methotrexate (DRUG), doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003376?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.